Further studies are necessary to better address whether RAS modulators that potentiate the ACE2 /Ang-(1-7) /Mas receptor axis and/or inhibit the ACE2 /AngII /AT1 receptor axis may improve HD-associated neuronal loss and symptoms. This evidence concerns the gene ACE2 and Huntington disease.